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VEGF secretion by adipose tissue-derived regenerative cells is impaired un-
der hyperglycemic conditions via glucose transporter activation and ROS in-
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ABSTRACT
Transplantation of cultured adipose-derived regenerative cells (ADRCs) into ischemic tissues pro-
motes neovascularization and blood perfusion recovery. These effects are attenuated in diabetes 
patients. We examined the effects of hyperglycemia on the angiogenic capacity of ADRCs derived 
from Wistar rats both in vivo and in vitro. Cultured ADRCs were predominantly composed of 
CD90 positive cells; prevalence of CD90 positive cells was not affected by hyperglycemia. mRNA 
and protein levels of vascular endothelial growth factor (VEGF) were significantly decreased in 
ADRCs under hyperglycemic conditions independent of osmolarity, whereas mRNA levels of he-
patocyte growth factor and fibroblast growth factor were unaffected. Since ADRCs express glu-
cose transporter proteins GLUT1, 3 and 4, we examined the effects of the glucose transporter 
inhibitor phloretin on reactive oxygen species (ROS) and angiogenic factors. Phloretin decreased 
the glucose uptake rate, reduced ROS, and increased VEGF mRNA in ADRCs exposed to a hy-
perglycemic condition. In vivo transplantation of ADRCs cultured under hyperglycemic conditions 
into mouse ischemic limbs resulted in significantly decreased blood perfusion and capillary densi-
ty in ischemic regions compared with transplantation of ADRCs cultured under normoglycemic 
conditions. These results suggest that hyperglycemia impaired VEGF production in ADRCs via an 
increase of ROS, impairing the angiogenic capacity of ADRCs transplanted into ischemic limbs.
Peripheral artery disease (PAD) is a progressive con-
dition characterized by stenosis and occlusion of the 
leg arteries, developing from a symptomatic condi-
tion known as claudication to critical limb ischemia 
(15). Although several procedures such as percuta-
neous transluminal angioplasty and bypass surgery 
are available for treating PAD, their clinical out-
come is not sufficient because of a high rate of re-
stenosis or a low rate of long-term patency of the 
arteries (4).
　Transplantation of stem or progenitor cells into 
ischemic tissues is emerging as a novel angiogenic 
therapy for the treatment of severe ischemic diseas-
es, with excellent outcomes in clinical trials (13). 
Endothelial progenitor cells, which migrate to an 
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MATERIALS AND METHODS
Isolation and culture of rat ADRCs. All protocols 
were approved by the Institutional Animal Care and 
Use Committee of Tottori University. Fresh ADRCs 
were isolated from the inguinal fat pad of Wistar 
rats (males, 8 weeks; CLEA Japan, Osaka, Japan) 
(18). Adipose tissues were minced and digested with 
1 mg/mL type I collagenase (Wako, Osaka, Japan). 
After filtration through a 100 μm-pore filter (BD 
Biosciences, San Jose, CA, USA), ADRCs were re-
covered by centrifugation (2,200 rpm for 5 min) and 
removal of adipocytes. ADRCs were cultured in Dul-
becco’s Modified Eagle Medium (DMEM; SIGMA-
Aldrich, St. Louis, MO, USA) supplemented with 
20% fetal bovine serum (FBS) and penicillin-strep-
tomycin-glutamine. Early passage cells were used in 
experiments. ADRCs were cultured under normogly-
cemic condition (with 5.5 mM glucose) for 3 pas-
sages and subsequently cultured in normoglycemic 
medium, high glucose (25 mM) medium, or normo-
glycemic but hyperosmotic medium with 19.5 mM 
mannitol for 2 weeks, and subjected to the further 
analyses.
Flow cytometric analysis. ADRCs were incubated 
with fluorescein conjugated antibodies against CD31 
[fluorescein isothiocynate (FITC); AbD Serotec, Ra-
leigh, NC, USA], CD45 [phycoeruthrin (PE); Bio 
Legend, San Diego, CA, USA], or CD90 [allophyco-
cyanin (APC); Miltenyi Biotec, Auburn, CA, USA] 
for 10 min at 4°C in 0.5% FBS and 2 mM EDTA in 
phosphate-buffered saline (PBS). Cells were also in-
cubated with fluorescein conjugated antibody against 
CD34 (FITC; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for 30 min at 4°C in 0.5% FBS 
and 2 mM EDTA in PBS. Labeled cells were run on 
a BD FACS CantII flow cytometer (BD Bioscienc-
es). Data were analyzed using BD FACS Diva soft-
ware (BD Biosciences).
Real-time reverse transcriptase-polymerase chain 
reaction analysis (RT-PCR). Extraction of total RNA 
from ADRCs was performed using RNeasy Mini kit 
(QIAGEN Inc., Valencia, CA, USA). Total RNA 
was extracted from frozen adductor skeletal muscle 
3 days after surgery with or without transplanted 
ADRCs using RNeasy fibrous tissue kit (QIAGEN 
Inc.). Real-time RT-PCR analysis of VEGF, hepato-
cyte growth factor (HGF), fibroblast growth factor-2 
(FGF-2) and β-actin mRNA, was performed using 
1 μg total RNA with ABI 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City, CA, 
ischemic site and differentiate into endothelial cells 
in vivo, are comprised in bone marrow-derived 
mononuclear cells (BM-MNCs) (2). However, the 
bone marrow contains a limited number of BM-
MNCs; therefore, a large volume of the bone mar-
row must be collected for therapeutic angiogenesis. 
Thus, an alternative source of stem or progenitor 
cells is necessary. Recently, several investigators 
have reported that adipose tissue contains multipo-
tent mesenchymal stem cells called “adipose-derived 
regenerative cells (ADRCs)” (23). Thus, the adipose 
tissue is an abundant source of regenerative cells 
available for autologous cell-transplantation; ADRCs 
can be easily obtained from adipose tissues with 
minimally invasive procedures. Furthermore, it has 
been reported that ADRCs secrete multiple angio-
genic growth factors that promote neovascularization 
(19), and that transplantation of cultured ADRCs 
into an ischemic site improves blood perfusion and 
increases tissue capillary density (10). Instead of 
BM-MNCs, therefore, ADRCs may be useful for an-
giogenic cell therapy.
　PAD is caused by arteriosclerosis in patients with 
life-style related diseases such as hypertension, hy-
perlipidemia and diabetes. Diabetes is one of the 
major risk factors causing PAD. Clinical studies 
demonstrated that angiogenesis by ADRCs was at-
tenuated in diabetes; ADRCs obtained from patients 
with diabetes type 1 or 2 had reduced abilities of 
proliferation and VEGF secretion (11). Experimental 
studies showed that human ADRCs cultured under 
hyperglycemic conditions exhibited decreased prolif-
eration potential (11). The functions of endothelial 
progenitors, muscle stem cells, and mesenchymal 
stem cells have been reported to be impaired when 
cultured in the presence of a high concentration of 
glucose (1). ADRCs isolated from diabetic rats and 
those cultured in medium containing high concentra-
tions of glucose showed impaired proangiogenic 
functions (9). These results indicated that angiogen-
ic properties of ADRCs might be impaired under 
hyperglycemic conditions. Yet, it remains unknown 
how angiogenic properties of ADRCs become im-
paired under such conditions.
　In the present study, we studied the effects of hy-
perglycemic conditions on secretion of angiogenic 
factors in ADRCs in vitro and in vivo, and found 
that elevation of intracellular glucose attenuated 
VEGF secretion by ADRCs via generation of reactive 
oxygen species (ROS), impairing neovascularization 
in ischemic muscles transplanted with ADRCs.
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was evaluated 0, 2, 3 and 4 weeks after surgery us-
ing a Laser Doppler Perfusion Imager (PERIMED, 
Stockholm, Sweden).
Measurement of tissue capillary density. Four weeks 
after surgery, the ischemic adductor skeletal muscle 
of recipient mice was isolated, embedded in Tissue-
Tek Optimal Cutting Temperature compound (Sakura 
Finetek Japan, Tokyo) and snap-frozen in liquid ni-
trogen. Cryostat sections (8 μm thick) of each tissue 
specimen were prepared and subjected to immuno-
histochemical analysis. Antibody specific for CD31 
(BD Biosciences) was used and labeled by the avi-
din-biotin complex technique and substrates (Vector 
Laboratories, Burlingame, CA). The cell positive for 
CD31 was defined as a vascular endothelial cell. 
Capillary density was expressed as ratios to the 
skeletal muscle density. Three randomly selected 
fields of transverse sections per animal (n = 3 for 
each group) were analyzed.
Statistical analysis. All values are the mean ± stan-
dard deviation (S.D.). To assess differences among 
groups, data were analyzed by Student’s t-test as-
suming equal variance. Other comparisons were per-
formed using Mann-Whitney U-test with StatView 
5.0 (SAS, Cary, NC, USA), where appropriate.
RESULTS
Surface markers of ADRCs cultured under normo-
glycemic and hyperglycemic conditions
ADRCs with surface makers CD31, CD34, CD45 
and CD90 were detected by flow cytometry. Analy-
sis of forward and side scatter characteristics indicat-
ed that ADRCs consisted of a single cell population 
under either normoglycemic or hyperglycemic con-
ditions (data not shown). ADRCs, whether cultured 
under normoglycemic or hyperglycemic conditions, 
expressed lower levels of the endothelial cell marker 
CD31 (0.3 ± 0.1% for normoglycemic vs. 0.3 ± 0.1% 
for hyperglycemic; n = 5 each), endothelial progeni-
tor cell marker CD34 (0.1 ± 0.1% for normoglyce-
mic vs. 0.2 ± 0.1% for hyperglycemic; n = 5 each), 
and leukocyte marker CD45 (0.3 ± 0.1% for normo-
glycemic vs. 0.2 ± 0.1% for hyperglycemic; n = 5 
each). Besides, they expressed a high level of the 
mesenchymal cell marker CD90 (95.8 ± 2.1% for 
normoglycemic vs. 95.4 ± 1.7% for hyperglycemic; 
n = 5 each).
USA). mRNA levels were expressed as ratios to the 
level of β-actin. The following primers were de-
signed to span genomic regions: 5’-GAG TTA AAC 
GAA CGT ACT TGC CAG A-3’ (forward) / 5’-ATT 
GGA TCA GGA CCT TGT GAG-3’ (reverse) for 
VEGF, 5’-ATT GGA TCA GGA CCT TGT GAG-3’ 
(forward) / 5’-CCA TTC TCA TTT TGT GTG TTC 
A-3’ (reverse) for HGF, 5’-TCT TCC TGC GCA 
TCC ATC-3’ (forward) / 5’-TCT TCC TGC GCA 
TCC ATC-3’ (reverse) for FGF-2, 5’-ACGTCCATT 
CTCCGTTTCAC-3’(forward) / 5’- TCCCACGGCC 
AACATAAG-3’ (reverse) for GLUT1, 5’-TTGCAG 
TGCCTGAGTCTTCTT-3’ (forward) / 5’-CCAGTC 
ACTCGCTGCTGA-3’ (reverse) for GLUT4, and 5’-
CTA AGG CCA ACC GTG AAA AG-3’ (forward) / 
5’-GCC TGG ATG GCT ACG ACA-3’ (reverse) for 
β-actin.
Assay of angiogenic factors. Secreted VEGF was 
measured by the enzyme-linked immunosorbent as-
say (ELISA; R&D Systems, Mineapolis, MN, USA), 
which was conducted according to manufacturer’s 
instruction.
Measurement of reactive oxygen species. ADRCs cul-
tured under hyperglycemic condition were incubated 
with or without 100 μM phloretin to inhibit glucose 
uptake, and then incubated with 2’,7’-Dichlorodihy-
drofluorescin diacetate (DCFH-DA) at 1 μM (Wako) 
at 37°C for 30 min. The fluorescence was detected 
by flow cytometry.
Measurement of glucose uptake. Before starting an 
assay, ADRCs were starved overnight in serum free 
medium. Cells were then incubated in DMEM con-
taining 25 mM 2-Deoxy-D-glucose (2DG) with or 
without 100 μM phloretin for 30 min. The rate of 
glucose uptake into ADRCs was determined by 2-h 
measurements using Glucose Uptake Fluorometric 
Assay Kit (BioVision, Inc., Milpitas, CA, USA).
Preparation of unilateral hind limb ischemia model 
and cell transplantation. Unilateral limb ischemia 
was induced in BALB/cAJcl-nu/nu mice (males, 8 ~ 
10 weeks). After the mice were anesthetized by in-
traperitoneal infusion of xylazine hydrochloride 
(5 mg/kg; Bayer, Tokyo, Japan) and ketamine hydro-
chloride (80 mg/kg; Sankyo Pharmaceuticals, Tokyo, 
Japan), the proximal right external iliac artery was 
ligated. Immediately after producing hind limb isch-
emia, ADRCs (3 × 106 cells in 40 μL volume per 
animal) or 40 μL of saline were injected into four 
sites of the ischemic adductor muscle. Blood flow 
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expressed in ADRCs under normoglycemic and hy-
perglycemic conditions. ADRCs expressed mRNA 
of GLUT1, 3 and 4, but not GLUT2. The mRNA 
level of any GLUT subtypes was not affected by 
hyperglycemic conditions. Next, the rate of glucose 
uptake by ADRCs was examined in the absence and 
presence of the glucose transporter inhibitor phlore-
tin under normoglycemic and hyperglycemic condi-
tions. Phloretin has been reported to equally inhibit 
GLUT1, 3 and 4 (8, 12, 20). Phloretin significantly 
decreased the rate of glucose uptake by ADRCs 
even under hyperglycemic conditions (Fig. 2B), 
while in the absence of the inhibitor the rates of 
glucose uptake were nearly equal under normoglyce-
mic and hyperglycemic conditions (data not shown). 
As shown in Fig. 2C, the level of ROS was signifi-
cantly increased under hyperglycemic conditions, 
with phloretin significantly decreasing ROS: ROS 
level determined as the fraction (%) of DCFH-DA 
positive cells averaged 8.1 ± 1.1 (normoglycemic), 
10.7 ± 0.3 (hyperglycemic), and 6.7 ± 0.3 (hypergly-
cemic plus phloretin) (each n = 3). Under hypergly-
cemic conditions the mRNA level of VEGF was 
significantly decreased, and phloretin treatment sig-
nificantly increased the level of VEGF mRNA 
(Fig. 2D): the level of VEGF mRNA as the ratio to 
that of β-actin mRNA averaged 0.113 ± 0.015 (nor-
moglycemic), 0.052 ± 0.011 (hyperglycemic), and 
0.079 ± 0.005 (hyperglycemic plus phloretin) (each 
n = 3), indicating the involvement of increased ROS 
in impaired production of VEGF.
Expression of mRNAs and proteins of angiogenic 
factors in ADRCs cultured under normoglycemic 
and hyperglycemic conditions
We determined several angiogenic factors expressed 
in ADRCs cultured under the normoglycemic (nor-
mal), hyperglycemic, and normoglycemic but hyper-
osmotic conditions. Real-time RT-PCR revealed that 
expression of VEGF mRNA (ratio to that of β-actin 
mRNA) was significantly lower in ADRCs cultured 
under hyperglycemic conditions (0.125 ± 0.043) than 
in those cultured under normoglycemic conditions 
(0.161 ± 0.043) or normoglycemic but hyperosmotic 
conditions (0.158 ± 0.034) (each n = 3) (Fig. 1A). 
There were no significant differences in the level of 
HGF and FGF-2 mRNAs among them: HGF levels 
were 0.00332 ± 0.00082 (normoglycemic), 0.00540 
± 0.00576 (hyperglycemic), and 0.00382 ± 0.00140 
(normoglycemic but hyperosmotic); FGF levels 
were 0.00209 ± 0.00017 (normoglycemic), 0.00232 
± 0.00045 (hyperglycemic), and 0.00203 ± 0.00021 
(normoglycemic but hyperosmotic) (each n = 3). The 
level of VEGF protein in cultured medium was also 
significantly lower when ADRCs were cultured un-
der hyperglycemic conditions (20.434 ± 3.767 ng/
mL) than when cultured under normoglycemic con-
ditions (30.121 ± 3.923 ng/mL) or hyperosmotic but 
normoglycemic conditions (29.842 ± 4.729 ng/mL) 
(Fig. 1B).
Effects of glucose transporter inhibitors on the ex-
pression of VEGF and ROS under hyperglycemic 
conditions
Fig. 2A shows the mRNA levels of GLUT subtypes 
Fig. 1　Production of VEGF in ADRCs cultured in a physiological solution with 5.5 mM glucose (normal), high glucose solu-
tion with 25 mM glucose (high), or normal glucose solution containing 5.5 mM glucose and 19.5 mM mannitol (mannitol). (A) 
Real-time RT-PCR analysis of VEGF mRNA expression level, which is expressed as the ratio to β-actin mRNA for copy 
numbers of each mRNA. (B) Secretion of VEGF from ADRCs. Concentration of VEGF in the culture medium was measured 
by ELISA assay. * P < 0.05 vs. high glucose, § P = 0.054 vs. high glucose.
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Effects of ADRCs implantation
To test whether ADRCs cultured under hyperglyce-
mic conditions have angiogenic effects in vivo, 
ADRCs cultured under the normoglycemic or hyper-
glycemic conditions were transplanted into the isch-
emic hind limb of recipient mice, and angiogenesis 
was evaluated by blood flow and capillary density 
measurements. Laser Doppler perfusion imaging 
analysis showed that blood perfusion in the isch-
emic limbs was significantly improved by ADRCs 
cultured under normoglycemic conditions but not by 
ADRCs cultured under hyperglycemic conditions, as 
compared with the control blood perfusion without 
injection of ADRCs (Fig. 3). As shown in Fig. 4, the 
capillary density in the ischemic limb muscle where 
ADRCs cultured under hyperglycemic conditions 
were injected was significantly lower than that in 
the ischemic limb muscle where ADRCs cultured 
under normoglycemic conditions were injected, and 
comparable with that in control ischemic limb mus-
cle without injection of ADRCs. Capillary density 
relative to the muscle bundle density at 3 different 
transverse sections obtained from 3 individual rats in 
each group averaged 0.247 ± 0.095 (without ADRCs), 
0.654 ± 0.214 (normoglycemic ADRCs), and 0.200 
± 0.063 (hyperglycemic ADRCs).
DISCUSSION
The expression of VEGF by ADRCs was suppressed 
both at the transcription and translation levels when 
these cells were cultured in the presence of high 
concentrations of glucose. This effect was not due to 
hyperosmolarity, because the hyperosmotic solution 
containing mannitol did not affect VEGF expression. 
ADRCs expressing GLUT1, 3 and 4 uptake excess 
Fig. 2　Effects of hyperglycemia and glucose transporter inhibition on glucose uptake, oxidative stress, and VEGF produc-
tion in ADRCs. (A) mRNA levels of GLUT1-4, as well as β-actin, expressed in ADRCs cultured under normoglycemic (left) 
and hyperglycemic (right) conditions. (B) The rate of glucose uptake into ADRCs in the absence and presence of phloretin, 
which was determined as the level of 2DG in ADRCs. (C) Flow cytometric analysis of ROS production detected by DCFH-
DA in ADRCs with normoglycemia (normal), hyperglycemia (high), or hyperglycemia and phloretin (high + phloretin). (D) Re-
al-time RT-PCR analysis of VEGF mRNA expression level, which is expressed as the ratio to β-actin mRNA for copy 
numbers of each mRNA. * P < 0.05 vs. high glucose, † P < 0.05 vs. high glucose and phloretin.
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markers such as CD13, CD49, CD44, CD90, and 
CD105 (18). We previously found that although 
freshly isolated ADRCs included CD31, CD34, and 
CD45 positive cells, CD90 positive cells became 
predominant during culture, which indicated prolif-
eration of only mesenchymal cells during culture (5). 
Under hyperglycemic conditions the predominance 
of CD90 positive cells was not affected, indicating 
that hyperglycemia does not influence the subpopu-
lation of ADRCs.
　There are many studies showing that the efficacy 
of cell transplantation therapy is mainly mediated by 
secretion of several angiogenic cytokines from trans-
planted cells (3, 14). Nakagami and coworkers (16) 
reported that cultured ADRCs secreted VEGF and 
HGF, which appear to mediate the efficacy of angio-
genic cell therapy. These cytokines are well known 
glucose under hyperglycemic conditions. Exposure to 
a high concentration of glucose increased ROS and 
impaired production of VEGF. The glucose trans-
porter blocker phloretin reduced ROS and restored 
the expression of VEGF mRNA. As compared with 
normal conditions, hyperglycemic conditions im-
paired the angiogenic action of ADRCs transplanted 
into mouse ischemic limbs, decreasing both blood 
perfusion and the capillary density of transplanted 
muscle. These results indicate that a high intracellu-
lar concentration of glucose in ADRCs impairs ex-
pression of VEGF via an increase of ROS, leading 
to impaired proangiogenic action.
　ADRCs are generally isolated from a heteroge-
neous mixture of stromal vascular fractions of adi-
pose tissue by their capacity to adhere to plastic 
culture dishes, and they express several surface 
Fig. 3　Recovery of blood perfusion in ischemic hind limbs by ADRC transplantation. (A) Representative images of isch-
emic lower limbs of mice in control (control) and with transplantation of ADRCs cultured under normoglycemic (normal) or 
hyperglycemic (high) conditions. The images were obtained 4 weeks after ligation of the right external iliac artery (injection 
of ADRCs). (B) Averaged time-dependent recovery of blood perfusion in ischemic hind limbs. Each bar represents the 
mean ± S.D. control, control group; normal, injected group with ADRCs cultured under normoglycemic conditions; high, in-
jected group with ADRCs cultured under hyperglycemic conditions. Ischemic regions were significantly reduced by injection 
of ADRCs cultured under normoglycemic conditions but not by injection of ADRCs cultured under hyperglycemic conditions. 
*
 P < 0.05 vs. control group, † P < 0.05 vs. high.
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tors (22); 3) hyperglycemia increases ROS via 4 in-
dividual pathways of the mitochondrial electron 
transport chain, NO synthase, NADPH, and xanthine 
oxidase activation to modulate gene expression (6); 
and 4) hyperglycemia reduces endothelial NO syn-
thase phosphorylation and NO production to impair 
endothelial progenitor cells (EPCs) and EPC-related 
vascular repair (7). In the present study, the expres-
sion of VEGF mRNA and protein in ADRCs was 
reduced under hyperglycemic conditions leading to 
impairment of their angiogenic action.
　The most prominent finding in the present study 
was that glucose transporter inhibition decreased 
ROS production by ADRCs under hyperglycemic 
conditions, restoring expression of VEGF. A high in-
tracellular glucose concentration led to elevation of 
ROS and reduction of VEGF production but these 
were normal when cells were pretreated with phlor-
etin. These findings indicate that hyperglycemia in-
duces ROS via elevation of intracellular glucose 
concentration. It was reported that intracellular glu-
to promote cell proliferation, migration, and mobili-
zation (21). We previously found that cultured 
ADRCs expressed VEGF, HGF, and FGF-2 (5). It 
has been reported that hyperglycemia impairs the 
angiogenic properties of ADRCs; Kim et al. (9, 11) 
reported that rat and human adipose derived stem 
cells cultured in medium containing a high concen-
tration of glucose showed reduced proliferation and 
an impaired proangiogenic action in vitro, which 
could be partly due to ROS generation by chronic 
exposure to a high concentration of glucose. ROS 
and reactive nitrogen species are biologically active 
O2 derivatives considered as toxic molecules. In-
creased ROS production is recognized as a major 
cause of the clinical complication associated with 
diabetes. The mechanisms of high glucose-induced 
cellular dysfunction may be as follows: 1) hypergly-
cemia impairs the glutathione cycle to increase ROS 
by depleting NADPH (17); 2) hyperglycemia pro-
duces advanced glycation end products (AGEs) to 
thereby generate ROS via activation of AGE recep-
Fig. 4　Angiogenic effects of ADRC transplantation into ischemic hind limbs of mice. The data were obtained 4 weeks after 
ligation of the right external iliac artery (injection of ADRCs). (A) Representative optical micrographs of muscular capillary in 
the ischemic limbs transplanted with ADRCs cultured under normoglycemic (normal) and hyperglycemic (high) conditions, as 
well as that without ADRC transplantation (control). (B) Averaged capillary density as the ratio to the skeletal muscle density 
in ischemic limbs without ADRC injection (control), with normoglycemic ADRC injection (normal), and with hyperglycemic 
ADRC injection (high). The capillary density in the ischemic limb muscle injected with hyperglycemic ADRCs was significantly 
lower than that in the ischemic limb injected with normoglycemic ADRCs. * P < 0.05 vs. high glucose, † P < 0.05 vs. control.
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cose increased ROS through activation of glucose 
transporters, inducing inflammation and cellular 
apoptosis of vascular cells (9). However, it has nev-
er been proven that activated glucose transporters 
uptake excess glucose and thereby impair the angio-
genic action of ADRCs. This is the first report to 
show the involvement of glucose transporters in 
hyperglycemia-induced impairment of ADRCs an-
giogenic action. The precise mechanisms for the in-
volvement of subtypes of glucose transporters in 
ADRC-related angiogenesis need to be elucidated in 
future studies.
　The clinical implications of our results are obvi-
ous. ADRCs cultured under hyperglycemic conditions 
did not increase blood perfusion nor the capillary 
density in transplanted muscles in vivo. This indi-
cates that hyperglycemia reduces the angiogenic ef-
ficacy of ADRCs transplanted into the patients with 
diabetes. Lee et al. (11) reported that saphenous vein 
graft in diabetic patients yield lower colony forming 
unit values than that in normal individuals, which 
was consistent with the suppression of cell prolifera-
tion observed in a murine diabetic model (9). In the 
present study, VEGF production by ADRCs was im-
paired by a high concentration of glucose, which 
may explain the impaired neovascularization ob-
served in diabetic patients. Nevertheless, this could 
be normalized by treatment with a blocker of glu-
cose transporters; inhibition of glucose transporters 
would improve the angiogenic action of ADRCs in 
diabetes patients.
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